Agenus Shares Are Trading Lower. The Company Announced Updated Results From Its Phase 1 Clinical Trial of BOT/BAL Combination Therapy in Patients With Metastatic CRC That Is Not Microsatellite Instability-high or Deficient Mismatch Repair
Agenus 股价走低。该公司公布了其针对转移性结直肠癌患者的BOT/BAL联合疗法的1期临床试验的最新结果,这些患者不是微卫星不稳定性(高度或缺陷的错配修复)